PharmaCyte Biotech Inc (PMCB) — Financial Flexibility Index
PharmaCyte Biotech Inc (PMCB) has a Financial Flexibility Index of -0.12x as of April 2026. Free cash flow of $-1.39 Million (operating CF $-1.39 Million minus capex $0.00) represents 0% of total liabilities ($11.77 Million). Check cash flow reinvestment rate of PharmaCyte Biotech Inc to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
PharmaCyte Biotech Inc Financial Flexibility Index (2002–2026)
Historical Financial Flexibility Index trend for PharmaCyte Biotech Inc across 25 annual periods. For the full cash flow conversion analysis, see PMCB operating cash flow.
Annual Financial Flexibility Index for PharmaCyte Biotech Inc (2002–2026)
Year-by-year free cash flow to debt coverage for PharmaCyte Biotech Inc. Explore cash flow to debt ratio of PharmaCyte Biotech Inc to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2026 | -0.44x | $-5.15 Million | $-5.15 Million | $11.77 Million | ▲ +51.8% |
| 2025 | -0.91x | $-2.98 Million | $-2.98 Million | $3.28 Million | ▼ -761.2% |
| 2024 | -0.11x | $-2.15 Million | $-2.15 Million | $20.39 Million | ▲ +98.4% |
| 2023 | -6.47x | $-3.79 Million | $-3.79 Million | $586.58K | ▼ -10.6% |
| 2022 | -5.85x | $-4.12 Million | $-4.12 Million | $704.37K | ▼ -27.2% |
| 2021 | -4.60x | $-3.33 Million | $-3.33 Million | $724.78K | ▼ -111.8% |
| 2020 | -2.17x | $-2.34 Million | $-2.34 Million | $1.08 Million | ▲ +44.0% |
| 2019 | -3.87x | $-2.88 Million | $-2.88 Million | $742.85K | ▲ +50.9% |
| 2018 | -7.89x | $-5.08 Million | $-5.08 Million | $644.17K | ▼ -37.0% |
| 2017 | -5.76x | $-3.34 Million | $-3.34 Million | $580.25K | ▲ +15.6% |
| 2016 | -6.82x | $-4.35 Million | $-4.35 Million | $637.64K | ▼ -200.8% |
| 2015 | -2.27x | $-4.56 Million | $-4.56 Million | $2.01 Million | ▼ -143.7% |
| 2014 | 5.18x | $1.94 Million | $-1.56 Million | $373.67K | ▲ +5144.3% |
| 2013 | -0.10x | $-390.43K | $-390.43K | $3.80 Million | ▼ -50.1% |
| 2012 | -0.07x | $-259.29K | $-259.29K | $3.79 Million | ▼ -23.4% |
| 2011 | -0.06x | $-220.15K | $-225.23K | $3.97 Million | ▲ +82.0% |
| 2010 | -0.31x | $-974.06K | $-974.06K | $3.15 Million | ▲ +23.7% |
| 2009 | -0.40x | $-1.18 Million | $-1.19 Million | $2.92 Million | ▲ +93.8% |
| 2008 | -6.48x | $-1.17 Million | $-1.19 Million | $180.56K | ▼ -323.2% |
| 2007 | 2.90x | $344.92K | $-351.60K | $118.81K | ▲ +297.3% |
| 2006 | -1.47x | $-1.06 Million | $-1.07 Million | $723.89K | ▲ +12.0% |
| 2005 | -1.67x | $-2.73 Million | $-2.80 Million | $1.63 Million | ▼ -212.5% |
| 2004 | -0.53x | $-176.03K | $-221.03K | $329.13K | ▲ +96.4% |
| 2003 | -14.84x | $-37.46K | $-37.46K | $2.52K | ▼ -429.9% |
| 2002 | -2.80x | $-21.99K | $-21.99K | $7.86K | — |